by goldfishadmin | Dec 9, 2024 | News
Funding to support preclinical development of Orphagen’s lead IBD candidate, OR-812, a first-in-class, small molecule inhibitor of the retinoic acid receptor alpha (RARα) SAN DIEGO–(BUSINESS WIRE)–Orphagen Pharmaceuticals, Inc., a biotech company...
by goldfishadmin | Nov 20, 2024 | News
The Cancer Prevention & Research Institute of Texas (CPRIT) announced today that it plans to award Orphagen a $10.2 M product development grant over three years to partially fund the final steps towards IND filing and a Phase 1 clinical trial of OR-449, a novel...
by Orphagen Pharma | Jan 17, 2023 | News, Uncategorized
SAN DIEGO–(BUSINESS WIRE)–Orphagen Pharmaceuticals, Inc., a biotech company pioneering the screening, discovery, and development of small molecule ligands that modulate orphan or unexplored members of the nuclear receptor family, today announced that the...
by goldfishadmin | Jun 11, 2022 | News
SAN DIEGO, June 11, 2022 – Orphagen Pharmaceuticals, an early-stage biopharmaceutical company focused on developing and commercializing novel therapies for cancer and other serious diseases with significant unmet need, today announced that additional data from...
by Orphagen Pharma | Apr 8, 2022 | News
SAN DIEGO, April 8, 2022 — Orphagen Pharmaceuticals Inc., a biotech company pioneering the screening, discovery, and development of small molecule ligands that modulate orphan or unexplored members of the nuclear receptor family, today announced a late-breaking...
by Orphagen Pharma | Oct 18, 2021 | News
Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that the National Cancer Institute (NCI) has indicated its intention to award the company $2.0 million under the Small Business Innovation Research (SBIR) program to support preclinical...
